英诺维瓦

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA)
  TipRanks · 2026/5/27
• 评级变动
  Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/4/8
• 评级变动
  TR | OpenAI - 4o Maintains Innoviva(INVA.US) With Hold Rating, Raises Target Price to $21.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/12
• 评级变动
  H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2025/12/16
• Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 公司公告
  Tianlong Group: Legal opinion of Beijing Guofeng Law Firm on the fulfillment of vesting conditions for some of the first vesting period in the second phase of the restricted stock incentive plan of Guangdong Tianlong Technology Group Co., Ltd. and the inva
  SZSI · 2022/8/16
• 评级变动
  H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2025/12/12
• Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• BTIG Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Oppenheimer Initiates Innoviva(INVA.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, Vs. FactSet Est of $111.0M
  MT Newswires · 2026/8/6
• 评级变动
  Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2025/12/15
• 评级变动
  Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2025/11/6
• 评级变动
  Oppenheimer Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  BTIG Initiates Innoviva(INVA.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/2/17
• 评级变动
  BTIG Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Goldman Sachs Maintains Innoviva(INVA.US) With Sell Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/5/7

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。